Bioconjugate companies develop technologies that chemically link biological molecules to drugs, imaging agents, polymers or other functional components. These approaches are used to improve targeting, stability, delivery and detection across therapeutics, diagnostics and life science research.
This category includes companies working on:
Browse 50 UK bioconjugate companies below.
Global biopharma with UK manufacturing, commercial and clinical operations
MSD is a global biopharmaceutical company discovering, developing, manufacturing and marketing medicines and vaccines across oncology, infectious disease, immunology, cardiometabolic disease and animal health. Its UK operations span pharmaceutical manufacturing at Cramlington, Northumberland, which supplies medicines…
Global pharma company in immunology, vaccines, and oncology
GSK is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of medicines and vaccines. Its pipeline and portfolio span respiratory and immunology, oncology, HIV (through its specialist subsidiary ViiV Healthcare), and infectious diseases including vaccines.…
Complex carbohydrate synthesis, catalogue products and CDMO services
Dextra Laboratories specialises in complex carbohydrate chemistry, supplying research products including oligosaccharides, monosaccharides, glycoconjugates and blood group antigens. It also offers contract development and manufacturing services for carbohydrate-based compounds, spanning discovery chemistry, process…
Target discovery platform and antibody-based therapies for oncology
Oxford BioTherapeutics is an Oxford-based clinical-stage oncology company discovering and developing first-in-class antibody-based cancer therapies. Its proprietary platform identifies novel membrane protein targets directly from patient tumour samples, enabling the development of ADCs, immuno-oncology antibodies,…
Clinical-stage antibody-drug conjugate developer for cancer
Iksuda Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugates for difficult-to-treat cancers. Its platform combines stable bioconjugation chemistry with tumour-selective payload activation to improve therapeutic index. Clinical programmes include IKS014, a HER2-targeting ADC, and…
Antibody fragment drug conjugate platform for solid tumour oncology
Antikor Biopharma is a pre-clinical stage biotechnology company developing antibody fragment drug conjugates for the treatment of solid tumours. The company's proprietary platform uses smaller antibody fragments rather than whole antibodies to achieve improved tumour penetration and faster systemic clearance compared…
ECM-targeted drug discovery platform for fibrosis and solid tumours
Engitix is a preclinical-stage biotechnology company developing therapeutics that target the extracellular matrix (ECM) in fibrosis and solid tumours. Its proprietary discovery platform integrates one of the largest ECM bioarchives with AI and machine learning to identify disease-specific targets and biomarkers.…
Chemical reagents and contract manufacturing for pharma and diagnostics supply chains
Biosynth Limited is the UK manufacturing and research entity of Biosynth, a global life sciences reagents and contract development and manufacturing organisation. Its Compton, Berkshire site specialises in complex chemical synthesis including carbohydrates, nucleosides, and enzyme substrates, supplying critical raw…
Multivalent linker technologies for antibody-drug conjugate therapeutics
Spirea is a biopharmaceutical company developing antibody-drug conjugate technologies for targeted cancer treatment. Its multivalent linker platform is designed to attach a wider range of drug payloads to antibodies while enabling higher payload loading and controlled delivery. Spirea conducts preclinical research on…
Targeted magnetic blood filtration to enable gene therapies
MediSieve is a biotechnology company developing selective magnetic blood filtration using engineered particles that bind specific circulating biological targets. Its extracorporeal system combines target-specific magnetic beads with a capture device designed to remove bound substances before blood returns to the…
Custom gene synthesis and molecular biology reagents for laboratory research
NBS Biologicals is a UK manufacturer and supplier of reagents, kits, biochemicals and labware for the laboratory research industry, combining its own expanding NBS product range with representation of major international brands. Through its parent company, the business offers custom gene synthesis and oligonucleotide…
Global biopharma with major UK R&D and regulatory operations
Pfizer Limited is the principal UK subsidiary of Pfizer Inc., one of the world's largest biopharmaceutical companies. Its Sandwich, Kent site houses pharmaceutical sciences, global clinical supplies, quality assurance, and worldwide safety and regulatory operations serving over 175 markets. A Devices Centre of…
Glycan analysis products and services for biopharmaceutical QC
Ludger is a glycobiology company specialising in the measurement and characterisation of protein glycosylation for biopharmaceutical development and quality control. The company manufactures glycan analysis kits, reagents, and reference standards for use in LC, MS, and CE workflows, and provides contract analytical…
CreaTap antibody engineering for improved solid tumour penetration
Creasallis is a biotechnology company developing antibody engineering technologies intended to improve drug delivery into solid tumours. Its patented CreaTap platform modifies therapeutic antibodies to promote deeper penetration into tumour tissue. The approach is under development for monoclonal antibodies,…
Specialty chemical building blocks and reagents for drug discovery research
Fluorochem is a UK manufacturer and supplier of specialty chemicals, reagents and biochemical building blocks, with a catalogue spanning several hundred thousand products used across chemistry, pharmaceuticals and medicinal chemistry research. The company's offering includes ADC linkers, PROTACs, bioconjugation tools…
Tumour-activated peptide drug conjugates for targeted oncology
Avacta Therapeutics is a clinical-stage biotechnology company developing peptide drug conjugates designed to deliver toxic chemotherapy payloads selectively within the tumour microenvironment. The company's delivery approach uses a short engineered peptide that masks the active payload until it is cleaved by…
Antibody-oligonucleotide conjugates for spatial biology and proteomics
AbOliGo is a biotechnology company developing antibody-oligonucleotide conjugates (AOCs) for multiplexed protein analysis, spatial biology and single-cell workflows. Its conjugation platform addresses a critical bottleneck in multiomic research, as fewer than 0.1% of commercially available antibodies are currently…
Global biopharma with UK R&D hub in Hertfordshire
Roche Products is the UK pharmaceutical arm of F. Hoffmann-La Roche, headquartered at Welwyn Garden City in Hertfordshire. The site employs over 1,900 people and serves as a primary hub for early-stage drug discovery, clinical development, computational sciences, and commercial operations. The UK operation contributes…
Complex molecule synthesis and chemistry-driven cancer drug discovery
New Path Molecular Research is a Cambridge-based chemistry company spun out from the laboratory of Professor Steve Ley at the University of Cambridge. The company specialises in the synthesis of complex functional molecules, including natural products, macrocycles and peptides, using flow chemistry and…
Integrated drug discovery CRO from target to clinical candidate
Sygnature Discovery is a UK-headquartered integrated drug discovery contract research organisation. Operating from sites in Nottingham, Alderley Park, and Glasgow, the company provides end-to-end drug discovery services spanning target identification, medicinal chemistry, in vitro bioscience, structural biology,…